Historic: Here's why CSL shares are looking very interesting right now

CSL's yield now rivals a big four bank…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As anyone who owns CSL Ltd (ASX: CSL) shares would be painfully aware, it has been a brutal few weeks to own this ASX 200 healthcare stock, and former market darling.

Back on 11 May, CSL lost almost 16% of its value in one session after reporting that it is expecting even lower revenues and profits than it had previously flagged for FY2026.

Investors responded by giving the company its worst one-day session in history. Of course, CSL was already on the nose with investors. Far from its halcyon days of over $340 a share in early 2020, the company lost more than half of its valuation between August 2025 and May 2026. And that was before that one-day car crash.

This has been devastating for many CSL investors, especially for those who have held on for years. The company today is at a price it first reached more than ten years ago. And it's not like CSL has paid out a lot in dividends over that time to make up for the loss of shareholder capital.

But now we are on the subject of dividends, let's dive in a little deeper, for something very interesting is happening on the CSL income front.

A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.

Image source: Getty Images

What's happening with the dividend on CSL shares?

As any good dividend investor knows, a company's dividend yield is the function of two metrics. The first is the raw dividends per share that a company declares and pays out. But that alone doesn't determine a company's dividend yield. It is also influenced by its share price. A company can increase its dividends every single year. Yet if its share price rises at an even faster rate, its running yield will fall. The opposite is also true, though, which brings us to CSL.

On the first factor, CSL remains a winner. The company has been growing its annual payouts for more than a decade. Its final dividend last year was the largest it has ever funded (in US dollar terms), coming in at US$1.62 per share. The interim dividend that investors bagged last month was tied for its largest interim payout, matching last year's US$1.30 per share.

If we combine this with the fact that CSL shares are at a ten-year low, it may come as no surprise to see that its yield is currently at a record high. For much of CSL's recent history, investors would be lucky to see the company trade on a yield above 1%. Today, it is sitting at 3.08% (at the time of writing), ahead of Commonwealth Bank of Australia (ASX: CBA), if you can believe it.

Of course, just because CSL is trading with an historically high dividend yield doesn't mean it's a screaming buy. If CSL's profits are sagging, the company might be forced to cut its payouts next year. This, as we've already discussed, would naturally bring the company's yield back down. Even so, it's a very interesting development to see this company hit a 3% dividend yield. Let's see what happens next.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 28% in a year, should I buy the dip on Resmed shares right now?

A leading analyst provides his outlook for the beaten-down ResMed share price.

Read more »

A businessman points to an arrow going up on a graph, indicating a share price rise for an ASX company.
Broker Notes

Up 1,277% in a year, why 4DMedical shares are tipped for more outsized gains

A leading analyst forecasts more outperformance from 4DMedical’s rocketing shares. But why?

Read more »

A person bounces another up high from a seesaw as the one in the air looks through a telescope into the future.
Healthcare Shares

Has the CSL share price finally bottomed out?

Is this beaten-down ASX healthcare giant finally turning a corner?

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Why everyone selling Cochlear shares right now could regret it in 3 years

Cochlear shares are down 65%. Here's why investors selling up right now could look back and wish they'd done the…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Healthcare Shares

Here's what brokers tip for CSL shares over the next 12 months

The beaten-down biotech company's shares are still falling.

Read more »

three excited doctors with hands in the air
Healthcare Shares

Pro Medicus announces $16m US contract renewal

Pro Medicus secures a major US contract renewal, strengthening its US footprint and underlining continued client retention.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

How much higher could Pro Medicus shares go? 2 brokers weigh in

New contract wins and a positive take on AI are tailwinds for this company.

Read more »

A bored man sits at his desk, flat after seeing the latest news on the share market.
Healthcare Shares

Why did CSL shares crash 22% in May?

Things went from bad to worse for this fallen giant last month.

Read more »